Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Shigemitsu Matsumoto

Mitsuhiro Ito

Koji Ono

Satoshi Yamamoto

Tomohiro Kaku

Shinji Morimoto

Yasushi Hattori

Takuto Kojima

Masashi Toyofuku

Masaki Daini

Norihito Tokunaga

Yuya Oguro

Taku Kamei

Takeshi Wakabayashi

Makoto Kamata

Jumpei Aida

Satoshi Sasaki

Minoru Nakamura

Shinji Nakamura

Masaki Seto

Shinichi Imamura

Kazuaki Takami

Nobuyuki Takakura

Tsuyoshi Maekawa

Masataka Murakami

Masaki Ogino

Satoshi Mikami

Toshitake Kobayashi

Eiji Kimura

Kouichi Iwanaga

Yasufumi Wada

Taisuke Tawaraishi

Yasuhisa Kohara

Naoyoshi Noguchi

Tomoko Ohashi

Sachie Takashima

Hiroyuki Kakei

Koji Watanabe

Toshio Tanaka

Hiroshi Banno

Atsushi Hasuoka

Kazuhiro Miwa

Hideki Furukawa

Takaharu Hirayama

Shizuo Kasai

Jinichi Yonemori

Yasufumi Miyamoto

Shuhei Ikeda

Yasuhiro Hirata

Seiji Miwatashi

Yusuke Tominari

Ayumu Niida

Naoki Miyamoto

Minoru Ikoma

Yayoi Nakayama

Yuko Hitomi

Takuya Fujimoto

Taisuke Katoh

Ryoma Hara

Hideto Fukushi

Hirotaka Kamitani

Takeshi Wakabaysahi

Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

Heterocyclic compound and use thereof

Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

Macrocyclic compound and use thereof

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Cyclopropanamine compound and use thereof

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof. 

The present invention provides a novel compound having a superior activity as an ERR-&#x3b1; modulator and useful as an agent for the prophylaxis or treatment of ERR-&#x3b1; associated diseases. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Nitrogen-containing heterocyclic compound

Growing community of inventors

Kanagawa, Japan

Shigemitsu Matsumoto